Goldman Sachs initiated coverage of Alkermes (ALKS) with a Buy rating and $43 price target The firm says the company’s “mature” portfolio of neuropsych assets are on track to achieve fiscal 2025 guidance while its orexin receptor 2 portfolio updates will drive share appreciation. Goldman is optimistic on the shares into the upcoming data.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- FDA flags possible safety signals in new report, says RBC Capital
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls
- Alkermes upgraded to Buy from Neutral at UBS
- Alkermes presenting new research related to ALKS 2680 at SLEEP 2025